Oncothyreon said it had enrolled its first patient in a phase one trial of its PX-866 drug. PX-866 is Oncothyreon’s fourth product candidate in clinical trials. The trial will enroll 63 patients with metastatic cancer who have failed or are intolerant of standard therapy. Read a release here. …

Almost two weeks ago now, I reported that Targeted Genetics’ initial press release announcing results from a study of its gene therapy for inflammatory arthritis was widely misinterpreted by various media outlets. That day, the company’s stock fell 11 percent. …

Seattle Genetics said today it started its sixth clinical trial of its SGN-40 therapy. The study involves both Velcade, an existing cancer treatment, and SGN-40 in patients with relapsed or refractory multiple myeloma. …

In the latest setback to the inhaled insulin market, Nektar Therapeutics said Wednesday that it would stop trying to find a marketing partner for its inhaled insulin drug Exubera, after clinical trials showed an increase in the number of new cases of lung cancer among patients who used the product. …

Loading...

More

Blog Search

Keyword search across all the entries in this blog.

Browse previous blog posts by month and year of entry. You'll see all the posts for that time period.

Select Month

Show Earlier

Browse previous blog posts by month and year of entry. You'll see all the posts for that time period.